Showing results (71-80 of 106) with videos related to
Sort By:
Pageof 11
Frontiers in Microbiology|November 17, 2025
New dengue virus inhibitors targeting NS3-NS5 interaction identified by in silico screeningGiulio Nannetti, Beatrice Mercorelli, Alessandro Bazzacco, et al.Antiviral Research|June 10, 2022
Discovery of novel SARS-CoV-2 inhibitors targeting the main protease Mpro by virtual screenings and hit optimizationBeatrice Mercorelli, Jenny Desantis, Marta Celegato, et al.Antiviral Research|August 8, 2024
Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovoAnna Bonomini, Jiwei Zhang, Han Ju, et al.Antimicrobial Agents and Chemotherapy|March 3, 2010
The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 proteinArianna Loregian, Beatrice Mercorelli, Giulia Muratore, et al.Journal of Medicinal Chemistry|June 7, 2014
Ethyl 1,8-naphthyridone-3-carboxylates downregulate human papillomavirus-16 E6 and E7 oncogene expressionManuela Donalisio, Serena Massari, Monica Argenziano, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 6, 2016
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirinSaverio G Parisi, Arianna Loregian, Samantha Andreis, et al.Journal of Medicinal Chemistry|April 10, 2015
A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) SubunitsSerena Massari, Giulio Nannetti, Jenny Desantis, et al.Plos One|November 21, 2012
The human cytomegalovirus DNA polymerase processivity factor UL44 is modified by SUMO in a DNA-dependent mannerElisa Sinigalia, Gualtiero Alvisi, Chiara V Segré, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|June 30, 2016
A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancerIsabella Monia Montagner, Anna Merlo, Debora Carpanese, et al.The Journal of Antimicrobial Chemotherapy|January 20, 2009
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosisFrancesca Gatti, Paola Nasta, Arianna Loregian, et al.Pageof 11